Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 23Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Carcinoma, Non-Small-Cell Lung 12Neoplasms 2Squamous Non-small Cell Lung Cancer 1NSCLC 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 58Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Drug Therapy 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4Palliative Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Neoplasms × Afatinib × Clear all
NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Shandong University

Recruiting
500 enrolled
Tumor-Agnostic

Neoplasms

NCT01251653 2016-05-30

A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Boehringer Ingelheim

Completed
94 enrolled 33 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡